<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Selected genetic syndromes associated with obesity&lt;sup&gt;[1-3]&lt;/sup&gt;</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Selected genetic syndromes associated with obesity<sup>[1-3]</sup></h1>
<div class="graphic"><div class="figure"><div class="ttl">Selected genetic syndromes associated with obesity<sup>[1-3]</sup></div><div class="cntnt"><table cellspacing="0"><colgroup span="6" width="16%"></colgroup> <tbody> <tr> <td class="subtitle1">Syndrome</td> <td class="subtitle1">MIM phenotype</td> <td class="subtitle1">Locus</td> <td class="subtitle1">Gene</td> <td class="subtitle1">Obesity onset (type)</td> <td class="subtitle1">Clinical features</td> </tr> <tr> <td>Albright hereditary osteodystrophy (pseudohypoparathyroidism type 1a)</td> <td><a href="https://www.omim.org/entry/103580" target="_blank">103580</a></td> <td>20q13.2</td> <td><em>GNAS1</em></td> <td>Early (generalized)</td> <td>Short stature, short metacarpals and metatarsals, round facies, delayed dentition, ±hypocalcemia and/or subcutaneous calcium or bone deposition (osteoma cutis), precocious puberty, mild cognitive deficit.</td> </tr> <tr class="highlight_lght_gray_text"> <td>Alström</td> <td><a href="https://www.omim.org/entry/203800" target="_blank">203800</a></td> <td>2p13</td> <td><em>ALMS1</em></td> <td>Age 2 to 5 years (central)</td> <td>Blindness, deafness, acanthosis nigricans, chronic nephropathy, type 2 diabetes, cirrhosis, primary hypogonadism in males only, normal cognition.</td> </tr> <tr> <td rowspan="15">Bardet-Biedl syndrome</td> <td><a href="https://www.omim.org/entry/209900" target="_blank">209900</a></td> <td>11q13</td> <td><em>BBS1</em></td> <td rowspan="15">Age 1 to 2 years (central)</td> <td rowspan="15"> <p>Intellectual disability, hypotonia, retinitis pigmentosa, polydactyly, hypogonadism±glucose intolerance, deafness, kidney disease.</p> Responds to treatment with setmelanotide<sup>*[3]</sup>.</td> </tr> <tr> <td><a href="https://www.omim.org/entry/615981" target="_blank">615981</a></td> <td>16q21</td> <td><em>BBS2</em></td> </tr> <tr> <td><a href="https://www.omim.org/entry/600151" target="_blank">600151</a></td> <td>3p12-q13</td> <td><em>BBS3</em> (<em>ARL6</em>)</td> </tr> <tr> <td><a href="https://www.omim.org/entry/615982" target="_blank">615982</a></td> <td>15q22.3-q23</td> <td><em>BBS4</em></td> </tr> <tr> <td><a href="https://www.omim.org/entry/615983" target="_blank">615983</a></td> <td>2q31</td> <td><em>BBS5</em></td> </tr> <tr> <td><a href="https://www.omim.org/entry/605231" target="_blank">605231</a></td> <td>20p12</td> <td><em>BBS6</em> (<em>MKKS</em>)</td> </tr> <tr> <td><a href="https://www.omim.org/entry/615984" target="_blank">615984</a></td> <td>4q27</td> <td><em>BBS7</em></td> </tr> <tr> <td><a href="https://www.omim.org/entry/615985" target="_blank">615985</a></td> <td>14q32</td> <td><em>BBS8</em> (<em>TTC8</em>)</td> </tr> <tr> <td><a href="https://www.omim.org/entry/615986" target="_blank">615986</a></td> <td>7p14</td> <td><em>BBS9</em></td> </tr> <tr> <td><a href="https://www.omim.org/entry/615987" target="_blank">615987</a></td> <td>12q</td> <td><em>BBS10</em></td> </tr> <tr> <td><a href="https://www.omim.org/entry/615988" target="_blank">615988</a></td> <td>9q33.1</td> <td><em>BBS11</em> (<em>TRIM32</em>)</td> </tr> <tr> <td><a href="https://www.omim.org/entry/615989" target="_blank">615989</a></td> <td>4q27</td> <td><em>BBS12</em></td> </tr> <tr> <td><a href="https://www.omim.org/entry/615990" target="_blank">615990</a></td> <td>17q23</td> <td><em>BBS13</em> (<em>MKS1</em>)</td> </tr> <tr> <td><a href="https://www.omim.org/entry/615991" target="_blank">615991</a></td> <td>12q21.3</td> <td><em>BBS14</em> (<em>CEP290</em>)</td> </tr> <tr> <td><a href="https://www.omim.org/entry/615992" target="_blank">615992</a></td> <td>2p15</td> <td><em>BBS15</em> (<em>C2ORF86</em>)</td> </tr> <tr class="highlight_lght_gray_text"> <td>Beckwith-Wiedemann</td> <td><a href="https://www.omim.org/entry/130650" target="_blank">130650</a></td> <td>11p15.5 in most cases; deregulation of imprinted genes including <em>IGF2</em></td> <td>Multiple</td> <td>–</td> <td>Hyperinsulinemia, hypoglycemia, hemihypertrophy, intolerance of fasting.</td> </tr> <tr> <td>Carpenter</td> <td><a href="https://www.omim.org/entry/201000" target="_blank">201000</a></td> <td>6p11</td> <td><em>RAB23</em></td> <td>(Central)</td> <td>Intellectual disability, short stature, brachycephaly, polydactyly, syndactyly of feet, cryptorchidism, umbilical hernia, high-arched palate, hypogonadism in males only.</td> </tr> <tr class="highlight_lght_gray_text"> <td>Cohen</td> <td><a href="https://www.omim.org/entry/216550" target="_blank">216550</a></td> <td>8q22</td> <td><em>COH1</em> (<em>VPS13B</em>)</td> <td>Mid-childhood (central)</td> <td>Intellectual disability, microcephaly, small hands and feet, cryptorchidism, hypotonia and failure to thrive in infancy, prominent central incisors; long, thin fingers and toes.</td> </tr> <tr> <td>Prader-Willi</td> <td><a href="https://www.omim.org/entry/176270" target="_blank">176270</a></td> <td>15q</td> <td> <p><em>NDN</em></p> <em>SNRPN</em></td> <td>Age 1 to 3 years (generalized)</td> <td>Early growth faltering followed by hyperphagia and increased weight gain by 2 to 3 years. Mild to moderate cognitive deficit, microcephaly, short stature, hypotonia, almond-shaped eyes, high-arched palate, narrow hands and feet, delayed puberty (but premature adrenarche).</td> </tr> </tbody></table></div><div class="graphic_lgnd">Listed conditions represent only a select list of genetic syndromes associated with obesity.</div><div class="graphic_footnotes">* Setmelanotide, a melanocortin 4 receptor agonist, is available for the treatment of obesity due to Bardet-Biedl syndrome or mutations (confirmed by genetic testing) in the <em>POMC</em>, <em>PCSK1</em>, or <em>LEPR</em> (leptin receptor) genes<sup>[3]</sup>. Refer to UpToDate content on genetic contributions to obesity.</div><div class="graphic_reference">References:
<ol>
<li>Kaur Y, de Souza RJ, Gibson WT, Meyre D. A systematic review of genetic syndromes with obesity. Obes Rev 2017; 18:603.</li>
<li>Leibel RL, Chua SC, Rosenbaum M. Obesity. In: The Metabolic and Molecular Bases of Inherited Disease, 8th ed, Scriver CR, Beaudet AL, Sly WS, Valle D (Eds), McGraw-Hill 2001. p.3965.</li>
<li>Imcivree (setmelanotide) injection, for subcutaneous use. US FDA approved product information; Rhythm Pharmaceuticals; June 2020. Available at: <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213793s001lbl.pdf" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213793s001lbl.pdf</a> (Accessed on June 17, 2022).</li>
</ol></div><div id="graphicVersion">Graphic 70658 Version 18.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
